N-DESMETHYL IMATINIB (BioDeep_00000804016)

   


代谢物信息卡片


N-DESMETHYL IMATINIB

化学式: C28H29N7O (479.2433464)
中文名称: N-去甲基伊马替尼, 伊马替尼杂质B
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCNCC3)NC4=NC=CC(=N4)C5=CN=CC=C5
InChI: InChI=1S/C28H29N7O/c1-20-4-9-24(17-26(20)34-28-31-12-10-25(33-28)23-3-2-11-30-18-23)32-27(36)22-7-5-21(6-8-22)19-35-15-13-29-14-16-35/h2-12,17-18,29H,13-16,19H2,1H3,(H,32,36)(H,31,33,34)

描述信息

同义名列表

1 个代谢物同义名

N-DESMETHYL IMATINIB



数据库引用编号

6 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有:

  • PubMed: 来源于PubMed文献库中的文献信息,我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表,这个列表按照代谢物同时出现的文献数量降序排序,取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘,得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序,取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中,存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称,可以跳转到相关代谢物的信息页面。



文献列表

  • Karin Skoglund, Johan Richter, Ulla Olsson-Strömberg, Jonas Bergquist, Warunika Aluthgedara, S J Kumari A Ubhayasekera, Svante Vikingsson, Anna Svedberg, Stina Söderlund, Anna Sandstedt, Anders Johnsson, Jesper Aagesen, Jonas Alsenhed, Staffan Hägg, Curt Peterson, Kourosh Lotfi, Henrik Gréen. In Vivo Cytochrome P450 3A Isoenzyme Activity and Pharmacokinetics of Imatinib in Relation to Therapeutic Outcome in Patients With Chronic Myeloid Leukemia. Therapeutic drug monitoring. 2016 Apr; 38(2):230-8. doi: 10.1097/ftd.0000000000000268. [PMID: 26693810]
  • A M Filppula, A Tornio, M Niemi, P J Neuvonen, J T Backman. Gemfibrozil impairs imatinib absorption and inhibits the CYP2C8-mediated formation of its main metabolite. Clinical pharmacology and therapeutics. 2013 Sep; 94(3):383-93. doi: 10.1038/clpt.2013.92. [PMID: 23657159]
  • Ali-Akbar Golabchifar, Mohammad-Reza Rouini, Bijan Shafaghi, Saeed Rezaee, Alireza Foroumadi, Mohammad-Reza Khoshayand. Optimization of the simultaneous determination of imatinib and its major metabolite, CGP74588, in human plasma by a rapid HPLC method using D-optimal experimental design. Talanta. 2011 Oct; 85(5):2320-9. doi: 10.1016/j.talanta.2011.07.093. [PMID: 21962649]
  • Andrea Davies, Alison K Hayes, Katy Knight, Sarah J Watmough, Munir Pirmohamed, Richard E Clark. Simultaneous determination of nilotinib, imatinib and its main metabolite (CGP-74588) in human plasma by ultra-violet high performance liquid chromatography. Leukemia research. 2010 Jun; 34(6):702-7. doi: 10.1016/j.leukres.2009.11.009. [PMID: 20004471]
  • Henrik Gréen, Karin Skoglund, Franz Rommel, Rajaa A Mirghani, Kourosh Lotfi. CYP3A activity influences imatinib response in patients with chronic myeloid leukemia: a pilot study on in vivo CYP3A activity. European journal of clinical pharmacology. 2010 Apr; 66(4):383-6. doi: 10.1007/s00228-009-0772-y. [PMID: 20054526]
  • Roos L Oostendorp, Tessa Buckle, Jos H Beijnen, Olaf van Tellingen, Jan H M Schellens. The effect of P-gp (Mdr1a/1b), BCRP (Bcrp1) and P-gp/BCRP inhibitors on the in vivo absorption, distribution, metabolism and excretion of imatinib. Investigational new drugs. 2009 Feb; 27(1):31-40. doi: 10.1007/s10637-008-9138-z. [PMID: 18449471]
  • Divya Menon-Andersen, John T Mondick, Bhuvana Jayaraman, Patrick A Thompson, Susan M Blaney, Mark Bernstein, Mason Bond, Martin Champagne, Michael J Fossler, Jeffrey S Barrett. Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults. Cancer chemotherapy and pharmacology. 2009 Jan; 63(2):229-38. doi: 10.1007/s00280-008-0730-x. [PMID: 18398615]
  • Aurélie Petain, Darouna Kattygnarath, Julie Azard, Etienne Chatelut, Catherine Delbaldo, Birgit Geoerger, Michel Barrois, Sophie Séronie-Vivien, Axel LeCesne, Gilles Vassal. Population pharmacokinetics and pharmacogenetics of imatinib in children and adults. Clinical cancer research : an official journal of the American Association for Cancer Research. 2008 Nov; 14(21):7102-9. doi: 10.1158/1078-0432.ccr-08-0950. [PMID: 18981009]
  • Stefan Pursche, Eberhard Schleyer, Malte von Bonin, Gerhard Ehninger, Samir Mustafa Said, Roland Prondzinsky, Thomas Illmer, Yanfeng Wang, Christian Hosius, Zariana Nikolova, Martin Bornhäuser, Gregor Dresemann. Influence of enzyme-inducing antiepileptic drugs on trough level of imatinib in glioblastoma patients. Current clinical pharmacology. 2008 Sep; 3(3):198-203. doi: 10.2174/157488408785747656. [PMID: 18781906]
  • Richard A Larson, Brian J Druker, Francois Guilhot, Stephen G O'Brien, Gilles J Riviere, Tillmann Krahnke, Insa Gathmann, Yanfeng Wang. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood. 2008 Apr; 111(8):4022-8. doi: 10.1182/blood-2007-10-116475. [PMID: 18256322]
  • Roos L Oostendorp, Jos H Beijnen, Jan H M Schellens, Olaf van Tellingen. Determination of imatinib mesylate and its main metabolite (CGP74588) in human plasma and murine specimens by ion-pairing reversed-phase high-performance liquid chromatography. Biomedical chromatography : BMC. 2007 Jul; 21(7):747-54. doi: 10.1002/bmc.816. [PMID: 17385801]
  • Jan H Beumer, James J Natale, Theodore F Lagattuta, Anastasios Raptis, Merrill J Egorin. Disposition of imatinib and its metabolite CGP74588 in a patient with chronic myelogenous leukemia and short-bowel syndrome. Pharmacotherapy. 2006 Jul; 26(7):903-7. doi: 10.1592/phco.26.7.903. [PMID: 16803422]
  • Edgar Faber, Jitka Nausová, Marie Jarosová, Merrill J Egorin, Milena Holzerová, Sárka Rozmanová, Ivana Maresová, Vladimír Divoký, Karel Indrák. Intermittent dosage of imatinib mesylate in CML patients with a history of significant hematologic toxicity after standard dosing. Leukemia & lymphoma. 2006 Jun; 47(6):1082-90. doi: 10.1080/10428190600565057. [PMID: 16840200]
  • Hans-Peter Gschwind, Ulrike Pfaar, Felix Waldmeier, Markus Zollinger, Claudia Sayer, Peter Zbinden, Michael Hayes, Rolf Pokorny, Michael Seiberling, Monique Ben-Am, Bin Peng, Gerhard Gross. Metabolism and disposition of imatinib mesylate in healthy volunteers. Drug metabolism and disposition: the biological fate of chemicals. 2005 Oct; 33(10):1503-12. doi: 10.1124/dmd.105.004283. [PMID: 16006570]
  • Periklis Pappas, Vasilis Karavasilis, Evangelos Briasoulis, Nicholas Pavlidis, Marios Marselos. Pharmacokinetics of imatinib mesylate in end stage renal disease. A case study. Cancer chemotherapy and pharmacology. 2005 Oct; 56(4):358-60. doi: 10.1007/s00280-005-1031-2. [PMID: 15883819]
  • Catherine Dutreix, Bin Peng, Guenther Mehring, Michael Hayes, Renaud Capdeville, Rolf Pokorny, Michael Seiberling. Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects. Cancer chemotherapy and pharmacology. 2004 Oct; 54(4):290-4. doi: 10.1007/s00280-004-0832-z. [PMID: 15138710]
  • Olivier Kretz, H Markus Weiss, Martin M Schumacher, Gerhard Gross. In vitro blood distribution and plasma protein binding of the tyrosine kinase inhibitor imatinib and its active metabolite, CGP74588, in rat, mouse, dog, monkey, healthy humans and patients with acute lymphatic leukaemia. British journal of clinical pharmacology. 2004 Aug; 58(2):212-6. doi: 10.1111/j.1365-2125.2004.02117.x. [PMID: 15255805]
  • Philipp le Coutre, Karl-Anton Kreuzer, Stefan Pursche, Malte v Bonin, Traugott Leopold, Gökben Baskaynak, Bernd Dörken, Gerhard Ehninger, Oliver Ottmann, Andreas Jenke, Martin Bornhäuser, Eberhard Schleyer. Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588. Cancer chemotherapy and pharmacology. 2004 Apr; 53(4):313-23. doi: 10.1007/s00280-003-0741-6. [PMID: 14658008]
  • Robert A Parise, Ramesh K Ramanathan, Michael J Hayes, Merrill J Egorin. Liquid chromatographic-mass spectrometric assay for quantitation of imatinib and its main metabolite (CGP 74588) in plasma. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2003 Jul; 791(1-2):39-44. doi: 10.1016/s1570-0232(03)00206-x. [PMID: 12798163]
  • R Bakhtiar, J Lohne, L Ramos, L Khemani, M Hayes, F Tse. High-throughput quantification of the anti-leukemia drug STI571 (Gleevec) and its main metabolite (CGP 74588) in human plasma using liquid chromatography-tandem mass spectrometry. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2002 Mar; 768(2):325-40. doi: 10.1016/s1570-0232(01)00611-0. [PMID: 11888061]